CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 200 enrolled
Drug / intervention
Isobutylamido-thiazolyl-resorcinol Cream 0.2% +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03926845
NCT03926845N/ACompleted

Efficacy and Tolerability of an Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Facial Hyperpigmentation, A Randomized Double-blind and Vehicle-Controlled Study

Institute of Dermatology, Thailand·interventional·Posted Apr 25, 2019·Updated Apr 6, 2022

In Brief

A clinical study evaluating Isobutylamido-thiazolyl-resorcinol Cream 0.2% and Vehicle for Facial Hyperpigmentation. Completed, enrolled 200 participants across 1 site.

Detailed Summary

Facial hyperpigmentation is a common skin issue that can cause embarrassment and affect the quality of life in majority of people. The investigators are conducting a research to study an efficacy and tolerability of Isobutylamido-thiazolyl-resorcinol 0.2% in lightening of the facial hyperpigmentation in comparison to vehicle intervention in 4, 8 and 12-week period. The ultimate goal is to provide the best cosmetic cream to improve the quality of life of people who suffer from facial hyperpigmentation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesThailand

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedApr 25, 2019
Enrollment StartApr 29, 2019
Primary CompletionNov 30, 2020
Study CompletionJan 31, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.2 years ago

Interventions

Isobutylamido-thiazolyl-resorcinol Cream 0.2%other

Each bottle contains Isobutylamido-thiazolyl-resorcinol cream 0.2% to be applied on the entire face twice daily for 12 weeks.

Vehicleother

Each bottle contains vehicle cream to be applied on the entire face twice daily for 12 weeks.